29.08USD-0.09%Mkt Cap: 2.56B USDP/E: —Last update: 2026-05-26
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral,…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap2.56B USD
Enterprise Value1.95B USD
Revenue (TTM)225.27M USD
Gross Profit-114.27M USD
Net Income (TTM)-113.70M USD
Revenue/Share2.543 USD
Last Price29.08 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45166A1025
Valuation
P/E (Trailing)—
P/E (Forward)-7.98
PEG—
EV/EBITDA-10.81
EV/Revenue8.67
P/S11.52
P/B2.54
EPS (TTM)-1.57
EPS (Forward)-3.70
52W Range
18.2551% of range39.28
52W High39.28 USD
52W Low18.25 USD
Profitability
Gross Margin-50.73%
Oper. Margin-1654.63%
EBITDA Margin-80.21%
Profit Margin-51.99%
ROE-11.11%
ROA-10.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.10M USD
CapEx (TTM)2.37M USD
FCF Margin-25.42%
FCF Yield-2.24%
Net Debt-642.60M USD
Net Debt/EBITDA3.56
Balance Sheet
Debt/Equity0.03
Current Ratio10.74
Quick Ratio10.45
Book Value/Sh11.65 USD
Cash/Share7.639 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)52.75 USD
Target Range36.00 USD – 81.00 USD
# Analysts16
Ownership
Shares Out.87.86M
Float87.01M
Insiders2.41%
Institutions110.04%
Short Interest
Short Ratio7.2d
Short % Float15.72%
Short % Out.13.32%
Shares Short11.71M
Short (prev mo.)9.76M
Technical
SMA 5030.85 (-5.8%)
SMA 20030.74 (-5.4%)
Beta-0.04
S&P 52W Chg28.31%
Avg Vol (30d)1.03M
Avg Vol (10d)803.57K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—